For patients who need semaglutide for obesity or weight management, that's a meaningful addition to the Canadian market
Side Effects In most cases, the administration of Ozempic (Semaglutide) 4 mg/3 ml does not lead to severe pain, serious allergic reactions, or any other health problems
This makes it beneficial not just for weight control, but also for metabolic health overall
FDA-labeled warnings include: Risk of thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) Pancreatitis (report severe abdominal pain, with or without vomiting) Gallbladder disease (including gallstones and cholecystitis) Acute kidney injury secondary to dehydration from gastrointestinal symptoms Hypoglycemia when used with insulin or insulin secretagogues (dose adjustments may be needed) Diabetic retinopathy complications in patients with type 2 diabetes and pre-existing retinopathy Suicidal behavior and ideation (monitor for depression or suicidal thoughts) Intestinal obstruction/ileus (particularly with severe constipation) These medications are contraindicated during pregnancy and should be discontinued at least two months before a planned pregnancy

It works by: Slowing gastric emptying, helping you feel fuller longer Suppressing appetite and reducing cravings, especially for high-calorie, processed foods Improving blood sugar control, even in non-diabetic patients Targeting the brains hunger signals, which reduces snacking and emotional eating Originally developed to treat type 2 diabetes under the brand name Ozempic, semaglutide is now FDA-approved for chronic weight management under the name Wegovy